Table 3.

Results of Statistical Analyses for Experiment 2 (AP-5 in PLS)

Source of variation	df	F	p
Phase 1: Sessions 1–5
Drug	1, 13	12.858	.003
Session	4, 52	3.490	.013
Drug × Session	4, 52	2.598	.047
Phase 2: Sessions 6–12
Drug	1, 13	10.605	.006
Session	6, 78	41.636	< .001
Drug × Session	6, 78	0.876	.516
Phase 3: Sessions 13–14
Drug	1, 13	7.598	.016
Session	1, 13	0.014	.907
Drug × Session	1, 13	0.353	.563

Note. AP-5 = 2-amino-5 phosphonopentanoic acid; PLS = posterior lateral striatum. Boldface indicates a significant effect of AP-5.